INVESTIGADORES
BRUZZONE Ariana
artículos
Título:
The BETA2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB-231 Cell Line
Autor/es:
RIVERO, E.M.; PEREZ PIÑERO, C; GARGIULO, L.; ENTSCHLADEN, F.; ZANKER, K.; BRUZZONE, A.; LUTHY, I.A.
Revista:
CURRENT CANCER DRUG TARGETS
Editorial:
BENTHAM SCIENCE PUBL LTD
Referencias:
Lugar: Oak Park; Año: 2017
ISSN:
1568-0096
Resumen:
Background: Breast cancer is the most diagnosed and the major cause of cancer death in women worldwide. Metastasisis the main cause of these deaths. The metastatic cascade involves multiple steps and it has been described that adrenergicreceptors can modulate this process at multiple levels. However, β-adrenergic action in breast cancer is controversial. Wehave previously shown that β-adrenergic agonists inhibit cell proliferation and tumor growth of numerous breast cancermodels. Objective: The purpose of the present investigation was to evaluate adrenergic effect in parameters related totumor progression (migration, invasion and metastases) in two human breast cancer cell lines. Method: Migration wasassessed in IBH-6 and MDA-MB-231 cells by time-lapse videomicroscopy and modified Boyden chambers. Invasion wasevaluated by Transwells coated with Matrigel and expression of pro-metastatic genes was determined by RT-qPCR.Experimental metastases studies were performed by injection of the cells in the tail vein of NSG immuno-deficient mice.Results: In both cell lines, salbutamol (β2-agonist) and propranolol (β-blocker) significantly diminished cell migrationwhile epinephrine exerted opposite effects. Moreover, salbutamol inhibited invasion of both breast cancer cell lines andenhanced adhesion to extracellular matrix. Salbutamol treatment was also able to decrease the expression of prometastaticgenes in MDA-MB-231 cells. Finally, this compound decreased the number and size of MDA-MB-231 lungexperimental metastases in NSG immuno-deficient mice. No effect on the establishment of IBH-6 metastases wasobserved. Conclusion: Our results suggest that salbutamol could be an effective adjuvant drug for the treatment ofmetastatic breast cancer.
